These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 3467144)

  • 1. A comparison of in vitro sensitivity of acute myeloid leukemia precursors to mitoxantrone, 4'deoxydoxorubicin, 4-demethoxydaunorubicin and daunorubicin.
    Schölzel C; van Putten W; Löwenberg B
    Leuk Res; 1986; 10(12):1455-9. PubMed ID: 3467144
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Toxicity of idarubicin and doxorubicin towards normal and leukemic human bone marrow progenitors in relation to their proliferative state.
    Minderman H; Linssen P; van der Lely N; Wessels J; Boezeman J; de Witte T; Haanen C
    Leukemia; 1994 Mar; 8(3):382-7. PubMed ID: 8127143
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activity of (7) anthracycline related compounds in an doxorubicin sensitive human small cell lung cancer line and its doxorubicin resistant descendant. Activity of doxorubicin, daunorubicin, 4-deoxyrubicin, 4-demethoxydaunorubicin, detorubicin, 4'-epidoxorubicin and mitoxantrone.
    Zijlstra JG; Meijer C; Timmer-Bosscha H; Le TK; de Vries EG; Mulder NH
    Eur J Respir Dis Suppl; 1987; 149():53-5. PubMed ID: 3034649
    [No Abstract]   [Full Text] [Related]  

  • 4. Cytotoxicity and DNA damage caused by 4-demethoxydaunorubicin and its metabolite 4-demethoxy-13-hydroxydaunorubicin in human acute myeloid leukemia cells.
    Limonta M; Biondi A; Giudici G; Specchia G; Catapano C; Masera G; Barbui T; D'Incalci M
    Cancer Chemother Pharmacol; 1990; 26(5):340-2. PubMed ID: 2208574
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Liposomal encapsulation of a synergistic molar ratio of cytarabine and daunorubicin enhances selective toxicity for acute myeloid leukemia progenitors as compared to analogous normal hematopoietic cells.
    Kim HP; Gerhard B; Harasym TO; Mayer LD; Hogge DE
    Exp Hematol; 2011 Jul; 39(7):741-50. PubMed ID: 21530609
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improved treatment results in high-risk pediatric acute myeloid leukemia patients after intensification with high-dose cytarabine and mitoxantrone: results of Study Acute Myeloid Leukemia-Berlin-Frankfurt-Münster 93.
    Creutzig U; Ritter J; Zimmermann M; Reinhardt D; Hermann J; Berthold F; Henze G; Jürgens H; Kabisch H; Havers W; Reiter A; Kluba U; Niggli F; Gadner H
    J Clin Oncol; 2001 May; 19(10):2705-13. PubMed ID: 11352963
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of relapsing and refractory adult acute myeloid leukemia according to in vitro clonogenic leukemic cell drug sensitivity.
    Delmer A; Marie JP; Thevenin D; Suberville AM; Zittoun R
    Leuk Lymphoma; 1993 May; 10(1-2):67-71. PubMed ID: 8374525
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro effect of P-glycoprotein (P-gp) modulators on drug sensitivity of leukemic progenitors (CFU-L) in acute myelogenous leukemia (AML).
    Marie JP; Helou C; Thevenin D; Delmer A; Zittoun R
    Exp Hematol; 1992 Jun; 20(5):565-8. PubMed ID: 1350249
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro sensitivity of leukemic clonogenic cells to four anthracyclines (adriamycin, daunorubicin, rubidazone and aclacinomycin) in human acute myeloid leukemia.
    Marie JP; Thevenin D; Zittoun R
    Nouv Rev Fr Hematol (1978); 1985; 27(3):163-7. PubMed ID: 3862071
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Human stem cell factor-antibody [anti-SCF] enhances chemotherapy cytotoxicity in human CD34+ resistant myeloid leukaemia cells.
    Lu C; Hassan HT
    Leuk Res; 2006 Mar; 30(3):296-302. PubMed ID: 16112192
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of Dose Ratio on Mitoxantrone and Daunorubicin in Acute Myeloid Leukemia: A Systematic Review and Meta-analysis of Randomized Controlled Trials.
    Deng L; Zhang C; Ying S; Cai B; Zhou F
    Clin Lymphoma Myeloma Leuk; 2021 Jan; 21(1):e10-e20. PubMed ID: 32863193
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro cytotoxicity of mitoxantrone, daunorubicin and doxorubicin in untreated childhood acute leukemia.
    Kaspers GL; Veerman AJ; Pieters R; van Zantwijk I; Klumper E; Hählen K; de Waal FC; van Wering ER
    Leukemia; 1994 Jan; 8(1):24-9. PubMed ID: 8289494
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antiproliferative activity of quercetin on normal bone marrow and leukaemic progenitors.
    Larocca LM; Teofili L; Leone G; Sica S; Pierelli L; Menichella G; Scambia G; Benedetti Panici P; Ricci R; Piantelli M
    Br J Haematol; 1991 Dec; 79(4):562-6. PubMed ID: 1772777
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sensitivities of AML blast stem cells to idarubicin and daunorubicin: a comparison with normal hematopoietic progenitors.
    Curtis JE; Minden MD; Minkin S; McCulloch EA
    Leukemia; 1995 Mar; 9(3):396-404. PubMed ID: 7533865
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative effects of G-CSF, GM-CSF and IL-3 on cytosine arabinoside- and daunorubicin-mediated cytotoxicity of acute myeloid leukemia cells and normal myeloid progenitors.
    Waga K; Furusawa S; Nagashima S; Saito K; Shishido H
    Int J Hematol; 1992 Aug; 56(1):17-27. PubMed ID: 1391803
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enhanced chemosensitivity in acute myeloid leukemia by hematopoietic growth factors: a comparison of the MTT assay with a clonogenic assay.
    te Boekhorst PA; Löwenberg B; Sonneveld P
    Leukemia; 1993 Oct; 7(10):1637-44. PubMed ID: 7692194
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enhanced chemosensitivity of clonogenic blasts from patients with acute myeloid leukemia by G-CSF, IL-3 or GM-CSF stimulation.
    te Boekhorst PA; Löwenberg B; Vlastuin M; Sonneveld P
    Leukemia; 1993 Aug; 7(8):1191-8. PubMed ID: 7688839
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination of hematopoietic growth factors containing IL-3 induce acute myeloid leukemia cell sensitization to cycle specific and cycle non-specific drugs.
    Tafuri A; Lemoli RM; Chen R; Gulati SC; Clarkson BD; Andreeff M
    Leukemia; 1994 May; 8(5):749-57. PubMed ID: 7514244
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Idarubicin in refractory acute leukemia.
    Fülle HH; Hellriegel KP
    Onkologie; 1986 Jun; 9(3):152-3. PubMed ID: 3528962
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro cytotoxicity of the LDE: daunorubicin complex in acute myelogenous leukemia blast cells.
    Dorlhiac-Llacer PE; Marquezini MV; Toffoletto O; Carneiro RC; Maranhão RC; Chamone DA
    Braz J Med Biol Res; 2001 Oct; 34(10):1257-63. PubMed ID: 11593299
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.